Physician profile
Christopher B Luring
NPI 1740413954
$508.02
in general payments reported to CMS, 2019-2025
15 companies · $41.08 in 2025
The $41.08 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $139 · 2021: $89.94 · 2022: $47.81 · 2023: $42.48 · 2024: $34.91 · 2025: $41.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $118.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $170.06 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $47.81 | 2022 | |
| Abbvie INC. | $38.04 | 2023-2025 | |
| Pacira Therapeutics, INC. | $37.23 | 2019-2020 | |
| Nevro Corp. | $34.91 | 2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $32.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $29.24 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $17.45 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.56 | 2020 | |
| Daiichi Sankyo INC. | $16.06 | 2019 | |
| Depuy Synthes Sales INC. | $14.70 | 2023 | Orthovisc, Monovisc |
| Sanofi-Aventis U.S. LLC | $14.26 | 2019 | |
| Merz North America, INC. | $13.82 | 2019 | |
| Pfizer INC. | $13.37 | 2023 | |
| Scilex Pharmaceuticals INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Luring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.